Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12DEH | ISIN: CH0256379097 | Ticker-Symbol: 6ML
Lang & Schwarz
02.05.24
18:28 Uhr
3,430 Euro
+0,100
+3,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULAR PARTNERS AG Chart 1 Jahr
5-Tage-Chart
MOLECULAR PARTNERS AG 5-Tage-Chart
RealtimeGeldBriefZeit
3,3503,51018:29
GlobeNewswire (Europe)
620 Leser
Artikel bewerten:
(2)

Molecular Partners: Life Science Cares Launches in Switzerland

First international chapter of Life Science Cares established in Switzerland - bringing hearts and minds together by empowering the life sciences industry to support local communities

ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geographies outside of the United States.

"We are excited to launch Life Science Cares Switzerland (LSCS) today, in time, to engage with the local community at the upcoming Swiss Biotech Day in Basel," said Nadine Zahnd, Managing Director of LSCS. "At the heart of our life sciences community is the overwhelming sense to act and do good. We are building bridges between Swiss Life Science Organizations and local charitable organizations for individuals who may otherwise fail to access the opportunities afforded to so many of us."

In Switzerland in 2021, 1.24 million people, including many families are considered at the brink of poverty. Those affected are at risk of losing their social contacts and often suffer from psychological and physical health problems. Children in such families face often insurmountable obstacle to reach their full potential. It is the mission of LSCS to break this cycle and offer a path to unlock opportunity.

At the Swiss Biotech Day, LSCS will be showcased in the Plenary Session on 22 April 2024 and in a dedicated Panel discussion featuring the Swiss Red Cross, Cooley LLP, Novartis, the Swiss Biotech Association (SBA) and Molecular Partners at 4.30 pm at Marriott Hotel in Basel. Information will be available for everyone who wishes to contribute to our mission at the SBA Booth.

The Board of LSCS will be constituted by Isabel Dalli, Novartis; Sarah MacDonald, CEO LSC, Inc.; Dorothea Bergler, Swiss Red Cross; Patrick Amstutz, Swiss Biotech Association / Molecular Partners; Dieter Gericke, Homburger; Christoph Schmidt, up&up communication.

Founding Members include Ulf Grawunder, Founder and former CEO of NBE Therapeutics; Bill Burns, former CEO of Roche Pharmaceuticals; Dominik Höchli, former Head of Global Medical Affairs at Abbvie; Patrick Amstutz, CEO of Molecular Partners and Chairman of Swiss Biotech Association, as well as Molecular Partners, OM Pharma, the Swiss Biotech Association, HBM Healthcare Investments and others.

About Life Science Cares Switzerland:
Life Science Cares Switzerland brings together the life science community and local non-profit organizations to build bridges for people with limited opportunities in our country. Our goal is to provide access to education and opportunity for all who wish to develop beyond their own limitations - by connecting the talents and minds of the life science community with the hearts of non-profit organizations. Learn more at www.lifesciencecares.ch

Contact:

Life Science Cares Switzerland

Nadine Zahnd-Straumann

Scheuchzerstrasse 35

CH-8006 Zürich

info@lifesciencecares.ch

www.lifesciencecares.ch


Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2024 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.